Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:BCTCVE:EMHNYSE:FRXNASDAQ:IPA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTBriaCell TherapeuticsC$10.60-3.8%C$10.60C$3.50▼C$15.75C$168.68MN/A12,671 shs3,402 shsEMHEmerald Health TherapeuticsC$0.26-3.8%C$0.26C$0.15▼C$0.53C$52.28MN/A644,760 shs384,329 shsFRXForest Road Acquisition$10.30$9.72▼$18.20$450MN/A2.07 million shs40,482 shsIPAImmunoPrecise Antibodies$1.63-0.3%$0.71$0.27▼$1.68$74.36M0.444.66 million shs168,695 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTBriaCell Therapeutics0.00%0.00%0.00%0.00%0.00%EMHEmerald Health Therapeutics0.00%0.00%0.00%0.00%0.00%FRXForest Road Acquisition0.00%0.00%0.00%0.00%0.00%IPAImmunoPrecise Antibodies+22.10%+53.77%+142.42%+323.38%+63.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTBriaCell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AFRXForest Road AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies1.7336 of 5 stars3.53.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTBriaCell Therapeutics 0.00N/AC$15.0041.51% UpsideEMHEmerald Health Therapeutics 0.00N/AN/AN/AFRXForest Road Acquisition 0.00N/AN/AN/AIPAImmunoPrecise Antibodies 3.00Buy$4.00145.40% UpsideCurrent Analyst Ratings BreakdownLatest EMH, BCT, FRX, and IPA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTBriaCell TherapeuticsN/AN/AC$3.34 per share3.17C$3.60 per shareN/AEMHEmerald Health TherapeuticsC$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64FRXForest Road AcquisitionN/AN/AN/AN/A$0.56 per shareN/AIPAImmunoPrecise Antibodies$18.16M4.11N/AN/A$0.93 per share1.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTBriaCell TherapeuticsN/A-C$0.38N/A∞N/AN/AN/AN/AN/AEMHEmerald Health TherapeuticsN/A-C$0.70N/A∞N/AN/AN/AN/AN/AFRXForest Road Acquisition-$7.92MN/A0.00N/AN/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies-$20.13M-$1.16N/AN/AN/A-190.76%-88.87%-49.26%8/4/2025 (Estimated)Latest EMH, BCT, FRX, and IPA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q4 2025IPAImmunoPrecise Antibodies-$0.02N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTBriaCell TherapeuticsN/AN/AN/AN/AN/AEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AFRXForest Road AcquisitionN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTBriaCell Therapeutics0.05129.63128.68EMHEmerald Health Therapeutics35.452.972.61FRXForest Road AcquisitionN/A0.370.37IPAImmunoPrecise Antibodies0.452.322.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTBriaCell TherapeuticsN/AEMHEmerald Health TherapeuticsN/AFRXForest Road AcquisitionN/AIPAImmunoPrecise Antibodies6.70%Insider OwnershipCompanyInsider OwnershipBCTBriaCell TherapeuticsN/AEMHEmerald Health TherapeuticsN/AFRXForest Road AcquisitionN/AIPAImmunoPrecise Antibodies6.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTBriaCell Therapeutics515.91 millionN/ANot OptionableEMHEmerald Health Therapeutics161205.03 millionN/ANot OptionableFRXForest Road AcquisitionN/A37.50 millionN/ANot OptionableIPAImmunoPrecise Antibodies8045.76 million42.64 millionNot OptionableEMH, BCT, IPA, and FRX HeadlinesRecent News About These CompaniesImmunoPrecise Antibodies Strengthens Board with Industry Veteran Jon LieberJuly 7 at 10:18 AM | tipranks.comImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training DataJuly 3, 2025 | businesswire.comImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® TechnologyJune 24, 2025 | businesswire.comWe're Keeping An Eye On ImmunoPrecise Antibodies' (NASDAQ:IPA) Cash Burn RateJune 18, 2025 | finance.yahoo.comAI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation StudiesJune 12, 2025 | financialpost.comFAI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation StudiesJune 12, 2025 | businesswire.comImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine DiscoveryJune 5, 2025 | businesswire.comImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement EffortsMay 21, 2025 | businesswire.comImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech ConferenceMay 20, 2025 | uk.finance.yahoo.comImmunoPrecise Antibodies to Present at Maxim Group’s 2025 Virtual Tech ConferenceMay 20, 2025 | tipranks.comImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech ConferenceMay 20, 2025 | businesswire.comIPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater SpeedMay 12, 2025 | finance.yahoo.comIPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater SpeedMay 12, 2025 | businesswire.comCarterra Announces its 2025 Symposia Series on Speeding Drug Discovery with AI/ML and Other New TechnologiesApril 24, 2025 | finance.yahoo.comImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing MethodsApril 11, 2025 | uk.finance.yahoo.comImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA’s Shift to Non-Animal Testing MethodsApril 11, 2025 | financialpost.comFImmunoPrecise Antibodies Partners with RIBOPRO to Enhance Antibody DiscoveryApril 10, 2025 | tipranks.comImmunoPrecise Antibodies (IPA) Upgraded to Buy: What Does It Mean for the Stock?April 3, 2025 | zacks.comImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2025 Earnings Call TranscriptApril 1, 2025 | msn.comImmunoPrecise Antibodies reports Q3 EPS (C$0.66) vs. (C$0.10) last yearMarch 29, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseAeva & Mobileye: LiDAR Stocks Powering the Autonomous RevolutionBy Dan Schmidt | July 2, 2025View Aeva & Mobileye: LiDAR Stocks Powering the Autonomous RevolutionEMH, BCT, IPA, and FRX Company DescriptionsBriaCell Therapeutics CVE:BCTC$10.60 -0.42 (-3.81%) As of 12/30/2021BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.Emerald Health Therapeutics CVE:EMHC$0.26 -0.01 (-3.77%) As of 04/26/2021Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.Forest Road Acquisition NYSE:FRXForest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.ImmunoPrecise Antibodies NASDAQ:IPA$1.62 -0.01 (-0.31%) As of 09:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Why Centene Stock Dropped 40% — And Whether It's a Buy Now D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
